Press Releases

Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate Governance SOUTH SAN FRANCISCO, Calif. , March 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.

Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting Therapy ALLO-316 Data Also Highlight the Potential of Dagger™ Technology, a Next Generation Allogeneic Platform

SOUTH SAN FRANCISCO, Calif. , March 02, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor

Publication Reviews Investigation of a Chromosomal Rearrangement Observed in a Single Patient Receiving Gene-Edited Allogeneic CAR T Treatment for Large B Cell Lymphoma Case Reveals Normal T Cell Biology Occurring in CAR T Cells, Including Notable Finding of Continued Chromosomal Rearrangement in

Initiated Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory (R/R) Large B Cell Lymphoma (LBCL) Presented Data Highlighting Industry-Leading Allogeneic CAR T Portfolio CD19 (ALLO-501/A): Six Month Durability and Progression Free Survival in R/R LBCL

Conference Call and Webcast Scheduled for 2:00 PM PT / 5:00 PM ET SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today

SOUTH SAN FRANCISCO, Calif. , Feb. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, presented preclinical data highlighting the Company’s next generation

Preclinical Efficacy and Safety Results Indicate AlloCAR T™ Development Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity SOUTH SAN FRANCISCO, Calif. , Jan. 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company

ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma SOUTH SAN FRANCISCO, Calif. , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company

SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor